Research Article

Angiodrastic Chemokines in Colorectal Cancer: Clinicopathological Correlations

George Emmanouil,1 George Ayiomamitis,2 Adamantia Zizi-Sermpetzoglou,3 Maria Tzardi,4 Andrew Moursellas,1 Argyro Voumvouraki,1,5 and Elias Kouroumalis1,5

1Gastroenterology Research Laboratory, University of Crete Medical School, Heraklion, Greece
2Department of Surgery, Tzanion General Hospital, Piraeus, Greece
3Department of Pathology, Tzanion General Hospital, Piraeus, Greece
4Department of Pathology, University of Crete Medical School, Heraklion, Crete, Greece
5Department of Gastroenterology & Hepatology, University Hospital of Heraklion, Heraklion, Crete, Greece

Correspondence should be addressed to George Emmanouil; emmanouil.george@gmail.com

Received 16 February 2018; Accepted 19 March 2018; Published 16 April 2018

Aim. To study the expression of angiodrastic chemokines in colorectal tumors and correlate findings with clinicopathological parameters and survival.

Methods. The proangiogenic factor VEGF, the angiogenic chemokines CXCL8 and CXCL6, and the angiostatic chemokine CXCL4 were measured by ELISA in tumor and normal tissue of 35 stage II and III patients and correlated with the histopathology markers Ki67, p53, p21, bcl2, EGFR, and MLH1 and 5-year survival. The Wilcoxon and chi-square tests were used for statistical comparisons.

Results. There was a significant increase of CXCL6 (p = 0.005) and VEGF (p = 0.003) in cancerous tissue compared to normal. Patients with lower levels of CXCL8 and CXCL4 lived significantly longer. Patients with loss of EGFR expression had higher levels of CXCL8 while p21 loss was associated with higher levels of CXCL6. Chemokine levels were not correlated with TNM or Dukes classification. Strong expression of p53 was accompanied by decreased survival.

Conclusions. (1) The angiogenic factors CXCL6 and VEGF are increased in colorectal cancer tissue with no association with the clinical stage of the disease or survival. (2) However, increased levels of tissue CXCL8 and CXCL4 are associated with poor survival. (3) Strong expression of p53 is found in patients with poor survival.

1. Introduction

The incidence of cancer is increasing every year. Colorectal cancer (CRC) is the second most common cause of cancer mortality in the Western world [1]. Many factors both environmental and genetic are implicated in the propagation and mortality caused by CRC. Among various trophic factors, chemokines have a predominant role.

Chemokines were originally considered to participate in the chemoattraction of leukocytes to inflammatory sites. Later, it became clear that chemokines and their receptors may also modulate tumor behavior through regulation of angiogenesis, activation of tumor cell proliferation, and metastasis [2].

There are several chemokine families. The CXC chemokine family is particularly implicated in the modulation of different cancers.

CXC chemokines are subdivided into ELR− and ELR+ subgroups based on the presence or absence of the ELR motif glu-leu-arg. ELR+ chemokines (CXCL1, 2, 3, 5, 6, 7, and 8) are angiogenic factors, whereas ELR− members are mostly angiostatic factors and inhibit the formation of new blood vessels that are critical for tumor expansion [3].

CXCL8 (IL-8) bears the ELR motif and is the most potent human neutrophil chemoattractant and activator [4]. CXCL8 is the first chemokine to be reported as an angiogenic factor [5]. Several studies describe an upregulation of CXCL8 in colon cancer cells and surrounding stromal...
cells [6–8] under the influence of various proinflammatory cytokines, such as IL-1β and TNF-α, and even microorganisms and hypoxia [9–13].

Several effects of CXCL8 favor the progression of colorectal adenocarcinoma. Thus, it induces transendothelial migration and increases the expression of intercellular adhesion molecule-1 (ICAM-1) on colon cancer cells resulting in extensive leukocyte adhesion to these cells [11]. There have been also reports that it mediates the binding of colon carcinoma cells to endothelial cells, which favors tumor cell invasion and metastasis [14], and importantly, it also promotes the outgrowth of newly formed vascular vessels thus providing critical oxygen and nutrients to the tumor [5, 15–17]. In addition, it acts as an autocrine growth factor for colon adenocarcinoma cells [14, 16–18].

CXCL6 (GCP2) is also an ELR+ CXC chemokine sharing 31% amino acid sequence homology with CXCL8 and similar properties. It stimulates the secretion of proteases such as matrix metalloproteinase-9 (MMP-9) from the granules of granulocytes [19–22]. CXCL6, like CXCL8, binds to the CXCR1 and CXCR2 receptors, which mediate their chemotactic and angiogenic activities [23–25].

VEGF is a strong angiogenic factor important for tumor neovascularization. Binding to three structurally similar receptors leads to endothelial cell proliferation, migration, survival, and angiogenesis [26, 27] which is further supported by extravasation of plasma proteins into the extravascular space, clotting formation, and deposition of fibrin that serves as matrix for the growth of new blood vessels and mesenchymal cells [28]. VEGF also attracts macrophages that may influence tumor progression [29].

CXCL4 is an ELR− CXC chemokine. Therefore, it is angiostatic and also inhibits endothelial cell chemotaxis [5, 30, 31]. CXCL4 is the first angiostatic chemokine described and has been shown to inhibit the angiogenic effects of VEGF and bFGF [32, 33]. There are two CXCL4 variants (CXCL4 and CXCL4L1) both with angiostatic properties, although CXCL4L1 is considered a more potent inhibitor of angiogenesis, differing only by three amino acids [31]. CXCL4 binds to the CXCR3 receptor [34, 35] but also inhibits angiogenesis via interaction with cell surface glycosaminoglycans or with angiogenic mediators and their receptors such as bFGF and CXCL8 [36–38].

There have been earlier studies on the expression of mostly angiogenic factors in colorectal carcinoma, but simultaneous studies of angiostatic and angiogenic chemokines are missing. We studied therefore the expression of two relatively less well-studied chemokines CXCL6 and CXCL4 along with the better-studied CXCL8 (IL-8) and VEGF in both carcinoma and adjacent noncancerous tissue and correlated with several cancer indices, trophic factors, and patient survival.

### 2. Patients

Patients with biopsy-confirmed colorectal cancers were recruited for participation in the current study. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the University Hospital of Heraklion, Heraklion. In all cases, written consent from the participants was obtained. Selection of patients was based on the following criteria:

(a) Only patients with stages II and III according to TNM classification (stages B and C according to Dukes classification as modified by Astler-Coller) were included. Metastatic disease (type IV) patients were excluded [39–41].

(b) Only patients with a curative (R0) surgical resection who did not receive adjuvant chemotherapy (either refused or were not considered as candidates by the attending doctors) were included.

(c) Only patients with at least a 5-year follow-up (or death before that) were included in the report. Patients lost to follow-up were not included.

In all, 35 patients operated for left colorectal adenocarcinoma fulfilled the criteria and were included in the study. Patient demographics are presented in Table 1.

At operation, once the tumor was resected, two tissue samples were collected, one from the tumor itself and a second from apparently normal mucosa about 10 cm away from the resection margin. Both samples were immediately frozen in liquid nitrogen and then stored at −80°C until studied. A standard pathological evaluation was done with the rest of the tumor specimen.

### 3. Pathology

For every patient, immunohistochemical detection of MLH1, Ki-67, bcl2, p53, and p21 and EGFR protein expression were
studied in tumor tissue by immunoperoxidase staining in 3 steps using a Dako kit as previously described [42].

Primary antibodies were antihuman M1L protein homologue-1 (MHL1), clone E 505 (ready for use, Dako), anti-Ki-67 (MIB-1Ab, dilution 1 : 80, Dako), anti-p53 (DO-7, dilution 1 : 100, BioGenex), anti-p21 (dilution 1 : 40, Dako), anti-bcl2 (dilution 1 : 10, BioGenex), and anti-EGFR (dilution 1 : 40, Dako). Tumors with known Ki-67, p53, and p21 and EGFR status were used as positive controls, whereas a normal lymph node served the same purpose for bcl2.

Ki-67, MLH1, bcl2, p53, and P21 expression was scored as previously described by two pathologists without knowledge of the clinical details [42] and according to previous studies [43–45]. EGFR expression was assessed according to the percentage of positive cells using the “0 to 2+” scale as follows: a score of 0 is an absence of positive cells; a score of 1 is >1–3%; and a score of 2+ is >4% positive cells.

4. Materials and Methods

Concentration of 4 chemokines (CXCL8, CXCL4, CXCL6, and VEGF) was calculated through ELISA protocols. All tissue samples, both cancer and control, were homogenized with a glass homogenizer in 1 ml 0.25% BSA phosphate-buffered saline (PBS) on ice. Immediately after homogenization, the samples were aliquoted and frozen at −80°C till further analysis. For each one of these chemokines, commercially available monoclonal antibodies and biotinylated antibodies were obtained (R&D Systems).

These antibodies were reconstituted with sterile Tris-buffered saline (TBS) according to the manufacturer’s instructions. After reconstitution, antibodies were aliquoted and stored at −20°C. Apart from the antibodies, commercially available recombinant human CXCL8, CXCL4, CXCL6, and VEGF were obtained (R&D Systems) to create solutions of known concentration for generating standard curves. Every sample was run in duplicate. Incubation times and antibodies’ concentrations were set in each protocol according to the manufacturer’s instructions.

Total tissue protein concentration was calculated in each homogenized sample using the bicinchoninic acid (BCA) method. Optical absorption was measured at 540 nm, and protein concentration was calculated through a standard curve with standards of known protein concentration. This method was preferred for our study as it can produce more accurate results in samples with high total protein concentration [46]. Chemokine concentrations were expressed as pg per ng of total protein.

5. Statistics

Statistical analysis was performed with the IBM SPSS statistics software version 19. Results are expressed as means ± standard deviation of the mean and were depicted as box plots. The nonparametrical test Wilcoxon signed-rank test for paired samples was used when the Kolmogorov-Smirnov method showed that the distribution of values was not normal. The chi-square test for the analysis of nonparametric data in 2 × 2 tables was used for associations between histopathology markers and 5-year survival. Statistical significance was set at the 5% level (p = 0.05).

6. Results

The Kolmogorov-Smirnov test showed that chemokine concentrations in both tumor and normal tissues were not normally distributed. Figure 1 shows that there are no significant differences between tumor and normal tissue for CXCL8 (p = 0.177) and CXCL4 (p = 0.795).

However, there was a significant difference for CXCL6 (p = 0.005) and VEGF (p = 0.003) between tumor and normal tissue.

7. 5-Year Survival

Due to lack of normality in distribution, the Wilcoxon test was used for comparisons. As shown in Table 2, there is a significant difference in 5-year survival for CXCL8 and CXCL4. Patients who survived had significantly lower levels of those chemokines as compared to nonsurvivors. The same tendency existed for CXCL6 and VEGF, but this was not statistically significant due to the high scattering of results.

Table 3 shows that increased expression of p53 is associated with a significantly reduced five-year survival, while patients with no expression of p21 and MLH1 tend to live longer, but this tendency was not significant statistically, possibly due to the relative small number of patients. Increased expression of EGFR was also associated with increased survival, but this also was not statistically significant.

8. Dukes Staging and TNM Staging

No difference of chemokine levels was found according to Dukes or TNM staging (Tables 4 and 5).

9. Histopathology Markers

9.1. Ki67, Bcl2, p53, and MLH1. Table 6 shows that there is no statistical difference between chemokine levels and expression of these markers. However, reduced expression of Ki67, p53, and MLH1 was associated with high, although nonsignificant, levels of CXCL6.

9.2. EGFR. Lack of expression of EGFR was associated with almost twice as high levels of CXCL8. On the other hand, no expression of EGFR was associated with reduced levels of CXCL6, but this was not significant due to high scattering of results. Results are shown in Table 7.

9.3. p21. As shown in Table 8, lack of expression of p21 is associated with significantly increased levels of CXCL6. By contrast, expression of p21 is associated with higher levels of VEGF, but this was not significantly different due to scattering of results.

10. Discussion

It is usually stated that bowel adenocarcinomas arise from epithelial cells. However, it is accepted today that the
interaction between tumor cells and the tumor microenvironment is equally important for tumor evolution. Among others, expression of angiodrastic agents is particularly effective as they can induce or inhibit neovascularization, a process vital for tumor progression [47, 48]. Colorectal cancer

Table 2: 5-year survival of patients according to chemokine levels. Wilcoxon signed-rank test for paired samples.

| Chemokine | 5-year survival | Mean (pg/ng protein) | Std deviation | p value |
|-----------|----------------|----------------------|---------------|---------|
| CXCL8 (cancer) | No | 8.17 | 3.82 | 0.028 |
| | Yes | 4.45 | 1.70 | |
| CXCL6 (cancer) | No | 15.13 | 19.17 | 0.841 |
| | Yes | 5.78 | 4.97 | |
| VEGF (cancer) | No | 101.33 | 96.37 | 0.306 |
| | Yes | 45.34 | 25.30 | |
| CXCL4 (cancer) | No | 603.03 | 307.42 | 0.028 |
| | Yes | 323.79 | 120.73 | |

Table 3: 5-year survival of patients according to histopathology expression. Chi-square test.

| Biomarker | Intensity scores | 5-year % alive | p value |
|-----------|----------------|----------------|---------|
| Ki67 | 1-2 | 33.3% | 1.000 |
| | 3 | 33.3% | |
| p53 | 0-2 | 57.1% | 0.036 |
| | 3 | 12.5% | |
| p21 | 0 | 50.0% | 0.264 |
| | 1-3 | 22.2% | |
| Bcl2 | 0 | 33.3% | 1.000 |
| | 1 | 33.3% | |
| MLH1 | 0 | 50.0% | 0.264 |
| | 1 | 22.2% | |
| EGFR | 0 | 16.7% | 0.264 |
| | 1-2 | 44.4% | |
is the second leading etiology of cancer death in Western countries. Almost half of the patients die of metastatic disease after curative surgery despite adjunct chemotherapy [49, 50]. TNM classification is considered to be the best prognostic factor in early stages of colon cancer [51].

In the present study, we measured in tumor tissue the quantity of the angiogenic chemokines CXCL6 and CXCL8 (IL-8) and the most widely studied angiogenic factor VEGF along with the angiostatic chemokine CXCL4. For comparisons, the same angiostatic chemokines were assessed in normal colonic tissue from the same patients.

Chemokines are implicated in cancer tumorigenesis and metastasis affecting tumor microenvironment mainly through development of local inflammation and angiogenesis [52].

CXC chemokines also attract neutrophils and lymphocytes thus modulating innate and adaptive immunity and interfering apoptosis, proliferation, and tumor cell metastases. Invasion and metastasis are dependent on a proangiogenic environment [53].

We have demonstrated that levels of two angiogenic factors, the chemokines CXCL6 and VEGF, are significantly higher in the malignant tissue compared with those in the normal tissue. Moreover, increased levels of two other chemokines the proangiogenic CXCL8 (IL-8) and the angiostatic CXCL4 are associated with a worse 5-year survival. Our findings for tissue levels of CXCL8 are different from those reported in the literature as we failed to demonstrate increased CXCL8 levels in the tumor tissue compared with those in the adjacent normal bowel. This is in disagreement with several reports that CXCL8 is upregulated in colon cancer cells and surrounding stromal cells in comparison with its normal counterparts [6–8, 54]. This is further supported in a recent study where CXCL8 expression was significantly upregulated in tumoral samples compared with that in normal tissue, and this upregulation increased with patients' age [55]. The exclusion of this discrepancy might be found in the report by Ning et al., where patients with stage IV CRC had more than 10 times higher serum level of CXCL8 compared with individuals with no evidence of disease [17]. Unlike other reports, we included only patients with disease stages II and III to avoid interference in survival by already present dissemination of the tumor, and this exclusion of stage IV patients where the highest values of CXCL4 are observed may explain our findings.

In an effort to see if chemokine levels are associated with survival and TNM or Dukes classification, we studied only patients who did not receive any adjunct chemotherapy after curative resection. In our study group, the overall 5-year survival was 55.1% similar to the previous study reporting stage-specific survival rates of 96%, 87%, 55%, and 5% for TNM stages I, II, III, and IV, respectively [56]. Interestingly, poor survival was related to increased CXCL8 and CXCL4 levels. The same tendency of increased levels in nonsurvivors also existed for VEGF, but this was not statistically significant. Our findings of CXCL8 and 5-year mortality are in agreement with previous reports where reduced overall survival in colorectal tumors is associated with high levels of CXCL8 [57–59]. In a large recent meta-analysis, increased levels of CXCL8 were associated with poor prognosis, but this was evident mostly in stage IV TNM patients while the association was weaker with overall survival [60]. This association is obviously due to the profound trophic effect of CXCL8 on human colon cancer cells along with increased peritumoral neoangiogenesis and extravasation of tumor cells into the liver and lung [61]. The detrimental effect of CXCL8 is further supported by its upregulation of MMPs from tumor cells hence increasing their potential for metastasis [62].

On the other hand, the association of CXCL8 with mortality may be related to the origin of CXCL8. An increased expression of CXCL8 in the peritumoral inflammatory infiltrate was associated with improved disease-free survival [63]. This is possibly due to the effect of CXCL8 on neutrophil recruitment. The proangiogenic effects of CXCL8 are independent from its chemotactic activity for neutrophils and other proinflammatory effects [64]. Neutrophils, attracted by CXCL8, might affect tumor development in two discrete ways depending on their phenotype. N1 tumor-associated neutrophils (TAN) contribute to tumor immune surveillance due to their cytotoxic ability and interaction [65].

Despite the fact that VEGF was significantly increased in tumor tissue compared with that in the adjacent normal tissue in our patients, there were no significant differences between VEGF levels and either histological classification (TNM and Dukes) or more importantly with patient survival. There are two possible explanations for this. First, the role of

| Chemokine     | Dukes staging | Mean (pg/ng protein) | Std deviation | p value |
|---------------|--------------|----------------------|---------------|---------|
| CXCL8 (cancer) | B            | 8.20                 | 4.53          | 0.773   |
|               | C            | 7.54                 | 4.30          |         |
| CXCL6 (cancer) | B            | 9.22                 | 11.56         | 1.000   |
|               | C            | 8.69                 | 12.23         |         |
| VEGF (cancer) | B            | 78.54                | 78.15         | 0.834   |
|               | C            | 70.71                | 72.20         |         |
| CXCL4 (cancer) | B            | 577.81               | 365.63        |         |
|               | C            | 574.45               | 333.62        | 0.773   |

| Chemokine     | TNM staging | Mean (pg/ng protein) | p value |
|---------------|-------------|----------------------|---------|
| CXCL8 (cancer) | II          | 7.73                 | 0.773   |
|                | III         | 7.98                 |         |
| CXCL6 (cancer) | II          | 9.44                 | 0.773   |
|                | III         | 8.38                 |         |
| VEGF (cancer)  | II          | 70.51                | 0.560   |
|                | III         | 79.91                |         |
| CXCL4 (cancer) | II          | 548.02               | 0.501   |
|                | III         | 607.55               |         |

Table 4: Chemokine levels according to Dukes classification. Wilcoxon signed-rank test for paired samples.
in nonsurvivors, but this was not statistically significant. However, that levels of VEGF in our study were also increased in endothelial cells that promotes the expression of endothelial cell production of CXCL8 [69, 70]. It should be noted that it is the relative expression of different chemokines and the resultant chemokine environment that influence the potential progression of colorectal tumors [74]. This may account for the association of the angiostatic CXCL4 with survival in our patients. It is plausible to assume that it is the balance of angiogenic and angiostatic factors that influences the end result in survival. We found increased levels of CXCL4 associated with decreased survival, but it may be postulated that these levels could not counteract the detrimental effect of CXCL8 and VEGF.

Data on CXCL6 in colorectal cancer are very limited. We found significantly increased levels of CXCL6 in tumor samples compared with those in the adjacent normal tissue. This is in agreement with the findings of Gjjsbers et al. [75] who detected CXCL6 in endothelial cells of colorectal adenocarcinomas, but not in endothelial cells of normal tissues.

The production of CXCL6 by endothelial cells within the tumor would imply that it might interfere with tumor development, invasion, and metastasis through neovascularization, but this is not substantiated by our findings since no differences were found in CXCL6 levels according to either TNM or Dukes classification. These are in contrast to other findings where no difference in either mRNA expression or protein concentration of CXCL6 between cancer and normal tissues was found probably due to the different patients studied [76].

Another interesting finding of our study is the lack of association of traditional histopathology markers with survival. Only patients with a strong expression of p53 had significantly decreased survival. It should be noted however that there was a trend for increased survival in patients with reduced expression of MLH1 and p21 and increased expression of EGFR, but this was not statistically significant.

High levels of VEGF expression have been associated with advanced cancer stage and related with unfavorable prognosis [71–73]. However, a recent publication may offer a more sound explanation. It was reported that the expression of CXCL4 in colon cancer seems to counterbalance the angiogenic effects of both VEGF and CXCL8. It is therefore possible that it is the relative expression of different chemokines and the resultant chemokine environment that influence the potential progression of colorectal tumors [74]. This may account for the association of the angiostatic CXCL4 with survival in our patients. It is plausible to assume that it is the balance of angiogenic and angiostatic factors that influences the end result in survival. We found increased levels of CXCL4 associated with decreased survival, but it may be postulated that these levels could not counteract the detrimental effect of CXCL8 and VEGF.

Table 6: Chemokine levels according to histopathology marker expression. Wilcoxon signed-rank test for paired samples.

| Intensity scores | CXCL8 (cancer) Mean (pg/ng protein) SD | CXCL6 (cancer) Mean (pg/ng protein) SD | VEGF (cancer) Mean (pg/ng protein) SD | CXCL4 (cancer) Mean (pg/ng protein) SD |
|-----------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| Ki67 | | | | |
| 1-2 | 7.97 3.43 NS | 11.06 14.66 NS | 104.62 101.73 NS | 486.85 170.26 NS |
| 3 | 7.77 4.97 | 7.78 10.09 NS | 51.3 27.81 | 638.46 416.03 NS |
| Bcl2 | | | | |
| −ve | 7.6 3.83 NS | 9.18 12.59 NS | 88.76 79.16 NS | 553.72 299.45 NS |
| +ve | 8.65 6.17 NS | 8.15 8.68 NS | 32.22 17.95 NS | 648.55 490.81 NS |
| p53 | | | | |
| −ve | 5.93 2.81 NS | 11.79 15.46 NS | 80.71 75.95 NS | 506.56 249.26 NS |
| +ve | 9.56 4.77 NS | 6.4 6.49 NS | 68.54 74.17 NS | 637.79 405.96 NS |
| MLH-1 | | | | |
| −ve | 8.89 5.35 NS | 11.18 12.92 NS | 102.39 102.61 NS | 588.84 391.89 NS |
| +ve | 7.12 3.47 NS | 7.72 11.19 NS | 53.03 28.96 NS | 567.07 316.73 NS |

Table 7: EGFR expression and chemokines. Wilcoxon signed-rank test for paired samples.

| Chemokine | EGFR intensity scores | Mean (pg/ng protein) SD | p value |
|-----------|-----------------------|-----------------------|---------|
| CXCL8 (cancer) | 0 | 10.17 3.91 | 0.012 |
| CXCL6 (cancer) | 1-2 | 5.78 3.61 | |
| VEGF (cancer) | 0 | 77.89 65.52 | 0.368 |
| CXCL4 (cancer) | 1-2 | 70.44 86.52 | 0.368 |

Table 8: Chemokine levels and p21 expression. Wilcoxon signed-rank test for paired samples.

| Chemokine | p21 Mean (pg/ng protein) SD | p value |
|-----------|-----------------------------|---------|
| CXCL8 (cancer) | −ve | 7.52 4.71 | 0.501 |
| +ve | 8.14 4.13 |
| CXCL6 (cancer) | −ve | 14.73 14.27 | 0.016 |
| +ve | 3.79 4.99 |
| VEGF (cancer) | −ve | 45.17 29.89 | 0.208 |
| +ve | 104.08 92.08 |
| CXCL4 (cancer) | −ve | 579.20 389.80 | 0.773 |
| +ve | 573.22 308.73 |
Interestingly, lack of expression of EGFR was accompanied in agreement with our finding similar to ours where increased levels of CXCL8 and CXCL6, respectively. Increased expression of EGFR was also associated with increased survival, but this was not statistically significant due to the relative small number of patients.

The expression of EGFR seems to be dependent on the site of tumor development. EGFR was positive in 92% of 619 tumor samples in a large series of colorectal tumors and EGFR expression correlated with favorable survival [89]. Another study of more than 10,000 tumors reported that EGFR expression was identified in approximately 45% of the left colon tumors, a finding similar to ours where 47% of patients were expressing EGFR [90]. In our study, increased expression of EGFR was also associated with increased survival, but this was not statistically significant. Interestingly, lack of expression of EGFR was accompanied by significantly higher levels of CXCL8 (Table 7). This is in agreement with our finding that increased levels of tumor CXCL8 are associated with decreased survival. An explanation for this might be the reported direct stimulation of cancerous cell proliferation by upregulation of EGFR and by proteolytic processing of EGFR ligands mediated by CXCL8 [91].

Microsatellite instability (MSI) is a form of genetic instability caused by alterations in the DNA mismatch repair system. MSI is due to a germline mutation in one of the mismatch repair genes (MLH1, MSH2, MSH6, and PMS2) or to epigenetic silencing of MLH1.

Methylation of the MLH1 promoter mediates gene silencing and leads to a reduction or loss of MLH1 expression. Loss of MLH1 expression is considered to be a rapid and reliable test in identifying MSI-H (high) phenotype of colorectal cancers [92, 93]. However, there is some confusion regarding mortality and MLH1 expression. Thus, loss of MLH1 expression was detected in approximately 90% of MSI-H carcinomas. Patients with MLH-1-negative carcinomas had increased mortality compared with those patients with MLH-1-positive tumors, but this was not significantly different [94]. On the other hand, MSI-H colorectal tumors have been associated with longer survival, better prognosis, and less tendency to metastasize than stage-matched tumors with microsatellite stability [95–98]. These reports are in agreement with our results. Our MLH1-negative patients tend to have a better 5-year survival, but as in the case of p21 expression, this was not statistically significant.

In conclusion, our results showed that the concentration of two angiogenic factors VEGF and CXCL6 is significantly increased in colorectal tumor tissue as compared with that in the adjacent normal tissue; therefore, they might be involved in local angiogenesis and tumor expansion. Moreover, significantly increased CXCL8 and CXCL4 levels were associated with a worse 5-year survival. The same nonsignificant trend was observed for VEGF. Chemokine levels were not related to histological tumor classification, but tumors with no expression of EGFR and p21 had significantly increased levels of CXCL8 and CXCL6, respectively.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

[1] L. Herszenyi and Z. Tulassay, “Epidemiology of gastrointestinal and liver tumors,” European Review for Medical and Pharmacological Sciences, vol. 14, no. 4, pp. 249–258, 2010.
[2] H. Verbeke, S. Struyf, G. Laureys, and J. Van Damme, “The expression and role of CXC chemokines in colorectal cancer,” Cytokine & Growth Factor Reviews, vol. 22, no. 5-6, pp. 345–358, 2011.
[3] R. Bonecchi, “Chemokines and chemokine receptors: an overview,” Frontiers in Bioscience, vol. No. 14, p. 540, 2009.
[4] J. Van Damme, J. Van Beeumen, G. Opdenakker, and A. Billiau, “A novel NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity,” The Journal of Experimental Medicine, vol. 167, no. 4, pp. 1364–1376, 1988.
[5] R. M. Strieter, P. J. Polverini, S. L. Kunkel et al., “The functional role of the ELR motif in CXC chemokine-mediated angiogenesis,” The Journal of Biological Chemistry, vol. 270, no. 45, pp. 27348–27357, 1995.
[6] R. Brew, S. A. Southern, B. F. Flanagan, I. W. McDicken, and S. E. Christmas, “Detection of interleukin-8 mRNA and protein in human colorectal carcinoma cells,” European Journal of Cancer, vol. 32, no. 12, pp. 2142–2147, 1996.
[7] G. Cui, A. Yuan, R. Goll, B. Vonen, and J. Florholmen, “Dynamic changes of interleukin-8 network along the colorectal adenoma–carcinoma sequence,” Cancer Immunology, Immunotherapy, vol. 58, no. 11, pp. 1897–1905, 2009.
[8] C. Rubic, V. O. Frick, S. Pfeif et al., “Correlation of IL-8 with induction, progression and metastatic potential of colorectal...
cancer,” *World Journal of Gastroenterology*, vol. 13, no. 37, pp. 4996–5002, 2007.

[9] J. M. Kim, S. J. Cho, Y. K. Oh, H. Y. Jung, Y. J. Kim, and N. Kim, “Nuclear factor-kappa B activation pathway in intestinal epithelial cells is a major regulator of chemokine expression and neutrophil migration induced by *Bacteroides fragilis* enterotoxin,” *Clinical and Experimental Immunology*, vol. 130, no. 1, pp. 59–66, 2002.

[10] S. K. Yang, L. Eckmann, A. Panja, and M. F. Kagnoff, “Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells,” *Gastroenterology*, vol. 113, no. 4, pp. 1214–1223, 1997.

[11] C. P. Kelly, S. Keates, D. Siegenberg, J. K. Linesvky, C. Pothoulakis, and H. R. Brady, “IL-8 secretion and neutrophil activation by HT-29 colonic epithelial cells,” *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 267, no. 6, pp. G991–G997, 1994.

[12] Y. Mizukami, W. S. Jo, E. M. Duerr et al., “Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells,” *Nature Medicine*, vol. 11, no. 9, pp. 992–997, 2005.

[13] C. C. Schuerer-Maly, L. Eckmann, M. F. Kagnoff, M. T. Falco, and F. E. Maly, “Colonic epithelial cell lines as a source of interleukin-8: stimulation by inflammatory cytokines and bacterial lipopolysaccharide,” *Immunology*, vol. 81, no. 1, pp. 85–91, 1994.

[14] A. Li, M. L. Varney, and R. K. Singh, “Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials,” *Clinical Cancer Research*, vol. 7, no. 10, pp. 3298–3304, 2001.

[15] R. M. Strieter, M. D. Burdick, B. N. Gomperts, J. A. Belperio, and M. P. Keane, “CXC chemokines in angiogenesis,” *Cytokine & Growth Factor Reviews*, vol. 16, no. 6, pp. 593–609, 2005.

[16] R. Brew, J. S. Erikson, D. C. West, A. R. Kinsella, J. Slavin, and S. E. Christmas, “Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro,” *Cytokine*, vol. 12, no. 1, pp. 78–85, 2000.

[17] Y. Ning, P. C. Manegold, Y. K. Hong et al., “Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo colon cancer cell line models,” *International Journal of Cancer*, vol. 128, no. 9, pp. 2038–2049, 2011.

[18] A. Sturm, D. C. Baumgart, J. H. d’Heureuse, A. Hotz, B. Wiedenmann, and A. U. Dignass, “CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway,” *Cytokine*, vol. 29, no. 1, pp. 42–48, 2005.

[19] P. Proost, C. De Wolf-Peeters, R. Conings, G. Opdenakker, A. Billiau, and J. Van Damme, “Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8,” *Journal of Immunology*, vol. 150, no. 3, pp. 1000–1010, 1993.

[20] R. M. Strieter, P. J. Poiverini, D. A. Arenberg, and S. L. Kunkel, “The role of CXC chemokines as regulators of angiogenesis,” *Shock*, vol. 4, no. 3, pp. 155–160, 1995.

[21] J. Vanderappellen, J. Van Damme, and S. Struyf, “The role of CXC chemokines and their receptors in cancer,” *Cancer Letters*, vol. 267, no. 2, pp. 226–244, 2008.

[22] J. Van Damme, A. Wuys, G. Froyen et al., “Granulocyte chemotactic protein-2 and related CXC chemokines: from gene regulation to receptor usage,” *Journal of Leukocyte Biology*, vol. 62, no. 5, pp. 563–569, 1997.

[23] J. Heidemann, H. Ogawa, M. B. Dwinell et al., “Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2,” *Journal of Biological Chemistry*, vol. 278, no. 10, pp. 8508–8515, 2003.

[24] A. Wuys, N. Van Osselaa, A. Haelens et al., “Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties,” *Biochemistry*, vol. 36, no. 9, pp. 2716–2723, 1997.

[25] M. Wolf, M. Belen Delgado, S. A. Jones, B. Dewald, I. Clark-Lewis, and M. Baggiolini, “Granulocyte chemotactic protein 2 acts via both IL-8 receptors, CXCR1 and CXCR2,” *European Journal of Immunology*, vol. 28, no. 1, pp. 164–170, 1998.

[26] Y. Aldebas, A. Rahman, A. Khan, and S. Aly, “The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy,” *International Journal of Clinical and Experimental Medicine*, vol. 6, no. 4, pp. 239–251, 2013.

[27] M. Kowanetz and N. Ferrara, “Vascular endothelial growth factor signaling pathways: therapeutic perspective,” *Clinical Cancer Research*, vol. 12, no. 17, pp. 5018–5022, 2006.

[28] H. Dvorak, L. Brown, M. Detmar, and A. Dvorak, “Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis,” *The American Journal of Pathology*, vol. 146, no. 5, pp. 1029–1039, 1995.

[29] V. Tchaikovski, G. Fellenbrich, and J. Waltenberger, “The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 28, no. 2, pp. 322–328, 2007.

[30] T. D. Shellenberger, M. Wang, M. Gujrati et al., “BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells,” *Cancer Research*, vol. 64, no. 22, pp. 8262–8270, 2004.

[31] S. Struyf, M. D. Burdick, P. Proost, J. van Damme, and R. M. Strieter, “Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis,” *Circulation Research*, vol. 95, no. 9, pp. 855–857, 2004.

[32] T. E. Maione, G. S. Gray, J. Petro et al., “Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides,” *Science*, vol. 247, no. 4938, pp. 77–79, 1990.

[33] S. K. Gupta and J. P. Singh, “Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression,” *The Journal of Cell Biology*, vol. 127, no. 4, pp. 1121–1127, 1994.

[34] H. Soto, W. Wang, R. M. Strieter et al., “The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3,” *Proceedings of the National Academy of Sciences*, vol. 95, no. 14, pp. 8205–8210, 1998.

[35] P. Romagnani, F. Annunziato, L. Lasagni et al., “Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity,” *Journal of Clinical Investigation*, vol. 107, no. 1, pp. 53–63, 2001.

[36] C. Perrot, Z. C. Han, C. Savona, J. P. Caen, and A. Bikfalvi, “Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization,” *Blood*, vol. 91, no. 9, pp. 3289–3299, 1998.

[37] A. Z. Dudek, I. Nesmelova, K. Mayo, C. M. Verfaillie, S. Pitchford, and A. Slungaard, “Platelet factor 4 promotes...
adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis," *Blood*, vol. 101, no. 12, pp. 4687–4694, 2003.

[38] E. Sulipce, M. Bryckaert, J. Lacour, J. O. Contreres, and G. Tobelem, "Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway," *Blood*, vol. 100, no. 9, pp. 3087–3094, 2002.

[39] C. E. Dukes, "The classification of cancer of the rectum," *The Journal of Pathology and Bacteriology*, vol. 35, no. 3, pp. 323–332, 1932.

[40] V. B. Astler and F. A. Coller, "The prognostic significance of direct extension of carcinoma of the colon and rectum," *Annals of Surgery*, vol. 139, no. 6, pp. 846–852, 1954.

[41] K. Washington, "7th edition of the AJCC cancer staging manual: stomach," *Annals of Surgical Oncology*, vol. 17, no. 12, pp. 3077–3079, 2010.

[42] G. D. Ayiomamitis, G. Notas, A. Zaravinos et al., "Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance," *Cancer*, vol. 77, no. 2, pp. 255–264, 1996.

[43] M. Hilska, Y. U. Collan, J. V. O Laine et al., "The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer," *Diseases of the Colon & Rectum*, vol. 48, no. 12, pp. 2197–2208, 2005.

[44] G. P. Smith, R. I. Kronh, G. T. Hermanson et al., "Measurement of protein using bicinchoninic acid," *Analytical Biochemistry*, vol. 150, no. 1, pp. 76–85, 1985.

[45] D. Hanahan and R. A. Weinberg, "The hallmarks of cancer," *Cell*, vol. 100, no. 1, pp. 57–70, 2000.

[46] C. Hemmings, "Is carcinoma a mesenchymal disease? The role of the stromal microenvironment in carcinogenesis," *Pathology*, vol. 45, no. 4, pp. 371–381, 2013.

[47] C. Twelves, A. Wong, M. P. Nowacki et al., "Capcetabine as adjuvant treatment for stage III colon cancer," *New England Journal of Medicine*, vol. 352, no. 26, pp. 2696–2704, 2005.

[48] T. André, C. Boni, L. Mounedji-Boudiaf et al., "Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer," *New England Journal of Medicine*, vol. 350, no. 23, pp. 2343–2351, 2004.

[49] T. André, C. Boni, M. Navarro et al., "Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial," *Journal of Clinical Oncology*, vol. 27, no. 19, pp. 3109–3116, 2009.

[50] G. Lazennec and A. Richmond, "Chemokines and chemokine receptors: new insights into cancer related inflammation," *Trends in Molecular Medicine*, vol. 16, no. 3, pp. 133–144, 2010.

[51] B. N. Gomperts and R. M. Strieter, "Chemokine-directed metastasis," *Contributions to Microbiology*, vol. 13, pp. 170–190, 2006.

[52] D. Doll, L. Keller, M. Maak et al., "Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival," *International Journal of Colorectal Disease*, vol. 25, no. 5, pp. 573–581, 2010.

[53] A. Nastase, L. Paslaru, V. Herlea et al., "Expression of interleukine-8 as an independent prognostic factor for sporadic colon cancer dissemination," *Journal of Medicine and Life*, vol. 7, no. 2, pp. 215–219, 2014.

[54] D. D. Alexander, J. Waterbor, T. Hughes, E. Funkhouse, W. Grizzle, and U. Manne, "African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review," *Cancer Biomarkers*, vol. 3, no. 6, pp. 301–313, 2007.

[55] H. Terada, T. Urano, and H. Konno, "Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer," *European Surgical Research*, vol. 37, no. 3, pp. 166–172, 2005.

[56] J. Dimberg, K. Strom, S. Lofgren, N. Zar, M. Lindh, and A. Matussek, "DNA promoter methylation status and protein expression of interleukin-8 in human colorectal adenocarcinomas," *International Journal of Colorectal Disease*, vol. 27, no. 6, pp. 709–714, 2012.

[57] Q. Liu, A. Li, Y. Tian et al., "The CXCL8-CXCR1/2 pathways in cancer," *Cytokine & Growth Factor Reviews*, vol. 31, pp. 61–71, 2016.

[58] W. Xia, W. Chen, Z. Zhang et al., "Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: a meta-analysis," *PLoS One*, vol. 10, no. 4, article e0123484, 2015.

[59] Y. S. Lee, I. Choi, Y. Ning et al., "Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis," *British Journal of Cancer*, vol. 106, no. 11, pp. 1833–1841, 2012.

[60] M. Luca, S. Huang, J. E. Gershwnwald, R. K. Singh, and M. Bar-Eli, "Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis," *The American Journal of Pathology*, vol. 151, no. 4, pp. 1105–1113, 1997.

[61] O. Oladipo, S. Conlon, A. O’Grady et al., "The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue," *British Journal of Cancer*, vol. 104, no. 3, pp. 480–487, 2011.

[62] A. Li, S. Dubey, M. L. Varney, B. J. Dave, and R. K. Singh, "IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis," *The Journal of Immunology*, vol. 170, no. 6, pp. 3369–3376, 2003.

[63] S. Tazzyman, C. E. Lewis, and C. Murdoch, "Neutrophils: key mediators of tumour angiogenesis," *International Journal of Experimental Pathology*, vol. 90, no. 3, pp. 222–231, 2009.

[64] S. Gurzu, J. Jung, L. Azamfere, T. Mezei, A. M. Cimpean, and Z. Szentirmay, "The angiogenesis in colorectal carcinomas with and without lymph node metastases," *Romanian Journal of Morphology and Embryology*, vol. 49, no. 2, pp. 149–152, 2008.

[65] F. Graziano and S. Cascini, "Prognostic molecular markers for planning adjuvant chemotherapy trials in Duke’s B colorectal cancer patients: how much evidence is enough?" *Annals of Oncology*, vol. 14, no. 7, pp. 1026–1038, 2003.

[66] R. W. C. Pang and R. T. P. Poon, "Clinical implications of angiogenesis in cancers," *Vascular Health and Risk Management*, vol. 2, no. 2, pp. 97–108, 2006.

[67] J. E. Nör, J. Christensen, J. Liu et al., "Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral..."
angiogenesis and accelerates tumor growth,” *Cancer Research*, vol. 61, no. 5, pp. 2183–2188, 2001.

[70] R. Schruefer, N. Lutze, J. Schymeinsky, and B. Walzog, “Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 288, no. 3, pp. H1186–H1192, 2005.

[71] S. Zheng, M. Y. Han, Z. X. Xiao, J. P. Peng, and Q. Dong, “Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma,” *World Journal of Gastroenterology*, vol. 9, no. 6, pp. 1227–1230, 2003.

[72] D. Cao, M. Hou, Y. S. Guan, M. Jiang, Y. Yang, and H. F. Gou, “Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications,” *BMC Cancer*, vol. 9, no. 1, p. 432, 2009.

[73] J. F. Liang, H. K. Wang, H. Xiao et al., “Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer,” *Journal of Experimental & Clinical Cancer Research*, vol. 29, no. 1, p. 71, 2010.

[74] H. Verbeke, G. De Hertogh, S. Li et al., “Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/ CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer,” *Human Pathology*, vol. 41, no. 7, pp. 990–1001, 2010.

[75] K. Gijsbers, M. Gouwy, S. Struyf et al., “GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors,” *Experimental Cell Research*, vol. 303, no. 2, pp. 331–342, 2005.

[76] C. Rubie, V. O. Frick, M. Wagner et al., “ELR+ CXCl chemokine expression in benign and malignant colorectal conditions,” *BMC Cancer*, vol. 8, no. 1, p. 178, 2008.

[77] A. Giatromanolaki, G. P. Statopoulos, E. Tsiohanou et al., “Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma,” *Cancer*, vol. 86, no. 8, pp. 1421–1430, 1999.

[78] A. Torsello, C. Garufi, M. Cosimelli et al., “P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevance,” *European Journal of Cancer*, vol. 44, no. 9, pp. 1217–1222, 2008.

[79] U. Manne, R. B. Myers, C. Moran et al., “Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma,” *International Journal of Cancer*, vol. 74, no. 3, pp. 346–358, 1997.

[80] H. Zavrides, A. Zizi-Sermpezoglou, I. Elemenoglou et al., “Immunohistochemical expression of bcl-2 in Dukes’ stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance,” *Polish Journal of Pathology*, vol. 56, no. 4, pp. 179–185, 2005.

[81] L. Poincloux, X. Durando, J. F. Seitz et al., “Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer,” *Surgical Oncology*, vol. 18, no. 4, pp. 357–365, 2009.

[82] A. C. Tsamandas, D. Kardamakis, T. Petas et al., “Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients’ outcome,” *In Vivo*, vol. 21, no. 1, pp. 113–118, 2007.

[83] T. Abbas and A. Dutta, “p21 in cancer: intricate networks and multiple activities,” *Nature Reviews Cancer*, vol. 9, no. 6, pp. 400–414, 2009.

[84] H. Mitomi, Y. Ohkura, N. Fukui et al., “P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis,” *European Journal of Gastroenterology & Hepatology*, vol. 19, no. 10, pp. 883–889, 2007.

[85] F. Prall, C. Ostwald, H. Nizze, and M. Barten, “Expression profiling of colorectal carcinomas using tissue microarrays: cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis,” *Applied Immunohistochemistry & Molecular Morphology*, vol. 12, no. 2, pp. 111–121, 2004.

[86] M. S. Lyall, S. R. Dundas, S. Curran, and G. I. Murray, “Profiling markers of prognosis in colorectal cancer,” *Clinical Cancer Research*, vol. 12, no. 4, pp. 1184–1191, 2006.

[87] L. Tornillo, A. Lugli, I. Zlobec et al., “Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach,” *American Journal of Clinical Pathology*, vol. 127, no. 1, pp. 114–123, 2007.

[88] S. Ogino, K. Nosho, K. Shima et al., “p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis,” *Cancer Epidemiology Biomarkers & Prevention*, vol. 18, no. 9, pp. 2513–2521, 2009.

[89] S. Koskensalo, J. Louhim, J. Hagström, M. Lundin, U.-H. Stenman, and C. Haglund, “Concomitant tumor expression of EGFR and TATI/SPINK1 associates with better prognosis in colorectal cancer,” *PLoS One*, vol. 8, no. 10, article e76906, 2013.

[90] M. E. Salem, B. A. Weinberg, J. Xiu et al., “Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers,” *Oncotarget*, vol. 8, no. 49, pp. 86356–86368, 2017.

[91] Y. Itoh, T. Joh, S. Tanida et al., “IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells,” *Cytokeine*, vol. 29, no. 6, pp. 275–282, 2005.

[92] C. R. Boland and A. Goel, “Microsatellite instability in colorectal cancer,” *Gastroenterology*, vol. 138, no. 6, pp. 2073–2087.e3, 2010.

[93] P. J. Cuyle and H. Preenen, “Current and future biomarkers in the treatment of colorectal cancer,” *Acta Clinica Belgica*, vol. 72, no. 2, pp. 103–115, 2016.

[94] G. Lanza, R. Gañà, I. Maestri, A. Santini, M. Matteuzzi, and L. Cavazzini, “Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability,” *Modern Pathology*, vol. 15, no. 7, pp. 741–749, 2002.

[95] Y. Niv, “Microsatellite instability and MLH1 promoter hypermethylation in colorectal cancer,” *World Journal of Gastroenterology*, vol. 13, no. 12, pp. 1767–1769, 2007.

[96] S. Popat, R. Hubner, and R. S. Housten, “Systematic review of microsatellite instability and colorectal cancer prognosis,” *Journal of Clinical Oncology*, vol. 23, no. 3, pp. 609–618, 2005.

[97] S. B. Lim, S. Y. Jeong, M. R. Lee et al., “Prognostic significance of microsatellite instability in sporadic colorectal cancer,” *International Journal of Colorectal Disease*, vol. 19, no. 6, pp. 533–537, 2004.

[98] J. Qu, Y. Jiang, H. Liu et al., “Prognostic value of E-cadherin-, CD44-, and MSH2-associated nomograms in patients with stage II and III colorectal cancer,” *Translational Oncology*, vol. 10, no. 2, pp. 121–131, 2017.